ONDCP director Sara Carter Bailey told Newsmax this week that marijuana is “still illegal” after the April 23 rescheduling order. The line is doing a lot of work. Schedule III moved state-licensed medical cannabis into the same federal category as ketamine and Tylenol with codeine. What’s still illegal in the strict sense is everything outside the medical lane, and the drug czar’s interview pointed exactly to the next enforcement targets: hemp THC, “high-potency” products and illicit grows.
“It’s still illegal,” Sara Carter Bailey told Newsmax this week.
The headlines treated the line as a clarification. It was closer to a policy memo.
Carter Bailey is the director of the White House Office of National Drug Control Policy. She was asked about the potency of marijuana products during an interview about the administration’s new National Drug Control Strategy. Her answer drew a hard line under what last month’s rescheduling order actually did.
“Executive-level Schedule III allows for doctors and research and for medicine, for medicinal purposes.”
That framing collapses a key distinction. Schedule III is not “illegal” in the lay sense. It is the same federal category as Tylenol with codeine, ketamine and testosterone, controlled substances with accepted medical use that are legal when prescribed. The April 23 order moved FDA-approved marijuana and state-licensed medical cannabis into that category. A Congressional Research Service report found that the order “appears to authorize end users to possess marijuana for medical use without a CSA-compliant prescription.” The industry around those patients remains in a gray zone, but the patients themselves are no longer in the “illegal” bucket Carter Bailey described.
What is still illegal, in the strict federal sense, is everything outside that medical lane. Recreational marijuana stays Schedule I. Most hemp THC products move to Schedule I on November 13, 2026. Any grow operation outside the state-license framework was never going to qualify. The drug czar’s three words elided the medical-versus-everything-else distinction at the heart of her own administration’s order.
And from there, the interview moved.
Key Takeaways
- Sara Carter Bailey, director of the White House Office of National Drug Control Policy, told Newsmax that the April 23 rescheduling order applies to state-licensed medical cannabis and FDA-approved products. Schedule III is the same federal category as Tylenol with codeine and ketamine, not a category of prohibited drugs. Recreational marijuana stays Schedule I.
- In the same interview, Carter Bailey raised alarm on “high-potency” cannabis citing a 90 percent THC figure, tied illicit marijuana grows to the Chinese Communist Party and Mexican cartels, and warned against “adversarial states” buying U.S. farmland to grow weed.
- The framing maps directly onto the administration’s new National Drug Control Strategy and the November 2026 federal recriminalization of most hemp THC products, signed into law by President Trump last fall.
The potency line, and what it actually means
Carter Bailey raised the alarm on “high-potency” cannabis, citing products she said reach “as high as 90 percent” THC. The figure deserves context Newsmax viewers are not getting. Flower does not test at 90 percent. Concentrates do, and they have for years, openly and legally, in regulated state markets.
The number does rhetorical work, not analytical work. It reads as a license to escalate, dressed up as data.
The administration’s new National Drug Control Strategy runs the same play. The document raises alarm about high-potency marijuana and its marketing, expresses concern that cartels and crime groups “exploit” state cannabis legalization laws, and walks readers toward the November 2026 federal recriminalization of most hemp THC products, signed into law by President Trump last fall.
“It’s still illegal. Executive-level Schedule III allows for doctors and research and for medicine, for medicinal purposes.”
Sara Carter Bailey, ONDCP director, on Newsmax
The foreign-grow pivot
The center of gravity in the interview was not Schedule III. It was the new enforcement target.
“We also have a problem out there with illicit marijuana grows,” Carter Bailey told Newsmax. “These are grows that are connected directly to the [Chinese Communist Party], grows connected directly to Sinaloa cartel and [Cártel Jalisco Nueva Generación], and we’ve seen the potency go as high as 90 percent in some products. So we are watching that. We’re monitoring that, and our law enforcement community is on board.”
She went further. “We should not allow adversarial states or adversaries to be purchasing farmland in the United States, even through straw men, to grow illicit marijuana and to not only poison our people, but poison our soil.”
This is the frame the administration has chosen for federal cannabis enforcement under a Schedule III regime. Not state operators. Not adult-use consumers. Foreign-linked illicit grows, packaged as a national security problem, dropped into the same segment as a public reminder that recreational weed remains Schedule I.
✅ What rescheduling did
Moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III
Ended 280E exposure for state-licensed medical operators
Authorized end-user medical possession under federal law, per the CRS report
Lowered federal research barriers for medical applications
❌ What the drug czar described next
Enforcement against “illicit grows” framed as national security and foreign-linked
Alarm campaign on “high-potency” cannabis under the new National Drug Control Strategy
November 2026 federal recriminalization of most hemp THC products
The hemp clock keeps running
Carter Bailey’s framing connects directly to the next federal cannabis fight. The shutdown deal Trump signed in November 2025 caps legal hemp at 0.4 milligrams of total THC per container and bans synthetic or chemically converted cannabinoids. The ban takes effect November 13, 2026. Most gummies, vapes, beverages, tinctures and low-dose products in the current hemp market move into Schedule I that day, unless Congress writes a new regulatory framework before then.
The administration’s drug strategy flags hemp THC products as a problem that prohibition will solve. The drug czar is publicly aligning the executive branch with that framing, on cable television, in the same interview where she narrows Schedule III down to medicine and research. States are already testing the edges of the ban. The federal posture is settled.
“We should not allow adversarial states or adversaries to be purchasing farmland in the United States, even through straw men, to grow illicit marijuana and to not only poison our people, but poison our soil.”
Sara Carter Bailey, ONDCP director, on Newsmax
The 2024 Carter Bailey and the 2026 one
Before her confirmation, Carter Bailey told an interviewer she had no problem with cannabis legalization “if it’s legalized and it’s monitored.” She called medical cannabis “a fantastic way of handling” cancer side effects. That posture helped get her through the Senate.
The posture from the ONDCP director’s chair is different. The 2026 version draws lines. Medical use, yes. Research, yes. Anything else, including most hemp THC products and any grow operation the administration can tie to a foreign actor, gets the enforcement treatment. Her early rollout already pointed in this direction. The Newsmax interview confirms it.
The bundle is the story
Rescheduling has been covered, including at this magazine, as a federal acknowledgment of medical value that stops short of legalization. That read still holds. What Carter Bailey added on Newsmax is the shape of what comes next. The administration is not done with weed. It just finished the easy part.
The headline was rescheduling. The strategy was everything else she said.
